Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EBS message board posts where the ticker symbol EBS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EBS SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-028232 Size: 4 KB
2018-06-12
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-006334 (34 Act)  Size: 13 KB
2018-06-12 001-33137
18891169
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-027713 Size: 14 KB
2018-06-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-027687 Size: 4 KB
2018-06-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-027686 Size: 4 KB
2018-06-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-027683 Size: 4 KB
2018-06-07
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001367644-18-000027 (33 Act)  Size: 225 KB
2018-05-30 333-225283
18868176
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-025992 Size: 4 KB
2018-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-025562 Size: 12 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-025560 Size: 12 KB
2018-05-24
More EBS SEC Filings


Related news from
Wed, 13 Jun 2018
14:51:01 +0000
Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth
Emergent Biosolutions Inc (NYSE: EBS ), a maker of vaccines and products for infectious diseases as well as chemical, biological or nuclear attacks, picked up a sell-side bull Wednesday.  The Analyst Argus ...
Fri, 08 Jun 2018
10:30:00 +0000
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
GAITHERSBURG, Md., June 08, 2018-- Emergent BioSolutions Inc. announced today that a member of the company’ s senior management team will present a corporate overview and discuss recent business developments ...
Thu, 07 Jun 2018
15:45:40 +0000
Emergent BioSolutions plans $50 million expansion to Baltimore facility
Maryland pharmaceutical firm Emergent BioSolutions Inc. has begun work on a $50 million expansion in Baltimore City. The multi-year expansion is expected to be completed in 2021, and will significantly increase the company’s contract development and manufacturing capacity, redundancy and flexibility. Emergent (NYSE:EBS), which is headquartered in Gaithersburg, has 1,300 employees working across 13 locations, including multiple facilities in Baltimore.
Thu, 07 Jun 2018
10:30:00 +0000
Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Emergent BioSolutions Inc. (EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is expected to be completed in 2021, and will significantly increase the company’s contract development and manufacturing capacity, redundancy, and flexibility. “The expansion of our Camden facility is a significant and impactful capital investment that will generate measurable benefits for our clients,” said Sean Kirk, senior vice president, manufacturing operations and CDMO business unit head.
Tue, 29 May 2018
11:40:00 +0000
Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.
Sun, 27 May 2018
22:00:00 +0000
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (EBS) under which Profectus and Emergent will receive up to $25 million to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Under the terms of the Framework Partnering Agreement for the collaboration among the three parties, Profectus will receive development funding from CEPI for advancing its Nipah virus vaccine and Emergent will provide technical and manufacturing support for the CEPI-funded program.
Fri, 25 May 2018
05:03:42 +0000
The latest outbreak of a deadly virus has scientists racing to create a vaccine
The Nipah virus outbreak in southern India this week has prompted the Coalition for Epidemic Preparedness Innovations (CEPI), a global alliance of governments and non-profits, to step up efforts to find a cure for the deadly disease. The virus has claimed the lives of at least 12 people over the past many days in the…
Thu, 24 May 2018
13:06:16 +0000
U.S. biotechs to speed work on Nipah vaccine as virus hits India
A global coalition set up a year ago to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India. The Coalition for Epidemic Preparedness Innovations (CEPI) said on Thursday that Profectus BioSciences and Emergent BioSolutions would receive up to $25 million to advance development and manufacturing of a shot for the bat-borne disease.
Thu, 24 May 2018
12:15:00 +0000
Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP, Destination XL Group, Allegiance Bancshares, and Emergent Biosolutions — Fundamental Analysis, Key Performance Indications
NEW YORK, May 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PGT, ...
Thu, 10 May 2018
20:50:52 +0000
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
GAITHERSBURG, Md., May 10, 2018-- Emergent BioSolutions Inc. has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning at 9:00 AM EDT at the Gaithersburg Marriott ...
Tue, 08 May 2018
20:43:00 +0000
Emergent BioSolutions Moves Things Around
Delayed shipments don't affect the bioterrorism company's 2018 forecast.
Mon, 07 May 2018
09:54:49 +0000
Edited Transcript of EBS earnings conference call or presentation 3-May-18 9:00pm GMT
Q1 2018 Emergent BioSolutions Inc Earnings Call
Fri, 04 May 2018
15:50:03 +0000
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
Fri, 04 May 2018
09:03:20 +0000
Emergent Biosolutions: 1Q Earnings Snapshot
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 10 cents. Losses, adjusted for non-recurring costs, were 3 cents per share. The results fell short of Wall Street expectations. ...
Thu, 03 May 2018
20:30:00 +0000
Emergent BioSolutions Reports First Quarter 2018 Financial Results
Reaffirms full year 2018 financial forecast and operational goals Provides Q2 2018 revenue forecast of $205 M- $230 M. GAITHERSBURG, Md., May 03, 2018-- Emergent BioSolutions Inc. reported financial results ...
Wed, 25 Apr 2018
19:38:27 +0000
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS ) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, ...
Thu, 19 Apr 2018
10:30:00 +0000
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
GAITHERSBURG, Md., April 19, 2018-- Emergent BioSolutions Inc. will host a conference call on Thursday, May 3, 2018 at 5:00 pm to discuss the financial results for the first quarter of 2018, recent business ...
Mon, 16 Apr 2018
12:03:01 +0000
See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EBS. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $497 million.
Fri, 13 Apr 2018
18:58:07 +0000
Emergent BioSolutions to enter 5 new countries with anthrax vaccine
The Gaithersburg-based biotech just received approval to introduce its anthrax vaccine in five European countries, a move that brings the possibility of a new and important revenue stream.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I have been a VF subscriber for one year and have found the members here generally to be informed, intelligent, articulate people of good will. The knowledge I've gathered has been well worth the price of tuition, and the subscription fee has been repaid many-fold in investment gains." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards